SFT is a relatively uncommon but distinctive mesenchymal neoplasm, originally described in the pleura cavity and later reported to occur ubiquitously [
1]. Although the histogenesis of SFT remains undetermined, recent studies strongly favor a primitive mesenchymal or perivascular cell origin [
10]. The kidney is a relatively infrequent site for SFT, with approximately at least 36 cases of renal SFT reported in a review article [
7]. Clinically, these cases were frequently considered to be malignant due to their large tumor size by physical examinations and radiographic studies. Symptoms do not differ from those reported by patients with renal cell carcinoma. Hypoglycemia, which is a rare symptom in intrathoracic and extrathoracic SFTs, was not reported in any renal SFTs including our case [
2].
Malignant behaviors in the form of recurrence and/or metastases can occur in 10% to 15% of intrathoracic SFTs and up to 10% of extrathoracic SFTs [
2,
3]. Malignant SFT is postulated to develop via two pathways: (1)
de novo occurrence or (2) dedifferentiation or sarcomatous overgrowth from a pre-exsisting histologically benign SFT [
1,
4]. Most renal SFTs were classified as histologically benign and showed a favorable prognosis, with no evidence of recurrence during a follow-up period ranging from 2 to 89 months [
7]. To our knowledge, two cases of malignant renal SFTs developing via dedifferentiation or sarcomatous overgrowth from a pre-existing benign SFT have been reported by Margo et al. and Fine et al., respecvievely [
7,
8]. A detailed comparison of the clinicopatholgoic features of these two cases and ours is summarized in Table . The tumor reported by Fine et al. had infiltrative borders and focal necrosis, and invaded beyond the renal capsule. The tumor described by Margo et al. was a 9-cm circumscribed mass devoid of either hemorrhage or necrosis. Notably, there was a 3-cm nodular area within the main tumor, microscopically responding to sarcomatous overgrowth. In contrast, our tumor showed a homogeneous cut surface with prominent necrosis and hemorrhage. Microscopically, the tumor reported by Fine et al. and Margo et al. showed typical features of benign SFT with 90% and 30% of dedifferentiation or sarcomatous overgrowth, respectively. In contrast, our tumor appeared to develop
de novo since we did not find any areas of dedifferentiation after extensive tumor sampling.
| Table 1Comparsion of the clinicopathologic features of malignant renal solitary fibrous tumor |
The criteria for clinical malignancy in intrathoracic SFT, first proposed by England et al. in 1989, include increased cellularity, pleomorphism, mitotic count more than 4 per 10 high power fields, necrosis, hemorrhage, size more than 10 cm, non-pedunculated and atypical locations (parietal pleura, pulmonary parenchyma) [
5]. The diagnostic criteria for malignant extrathoracic SFTs are purely microscopic and include increased cellularity, pleomorphism and mitotic count more than 4 per 10 high power fields [
4,
11]. Currently the impact of tumor characteristics (size, hemorrhage, necrosis and location) in predicting clinical malignancy in extrathoracic SFTs remains to be investigated. Our case fulfilled the diagnostic criteria for malignant extrathoracic SFTs. Additionally, the presence of hemorrhage and necrosis and a 20% Ki-67 proliferative index further supports a diagnosis of malignant renal SFT.
SFTs show a wide variety of microscopic growth patterns and should be distinguished from benign and malignant spindle cell tumors. Positive immunoreactivity for CD34 and CD99 is characteristic of SFT, and highly valuable in differentiating from other mesenchymal tumors [
2,
4]. However the expression of CD34 and CD99 may be decreased or absent in areas with marked atypia or dedifferentiation [
8,
12]. Genetic analyses of SFT to date have not found consistent and characteristic cytogenetic abnormalities that can be used an ancillary diagnostic marker. Missense mutation of platelet-derived growth factor receptor-β (PDGFR-β) has been reported in 2 of 88 pleuro-pulmonary SFTs [
13], but we did not detect PDGFR-β mutation in our case (data not shown).
The prognosis of extrapleural SFTs is more unpredictable than that of pleural tumors due to lack of large-scale studies. The clinical outcomes were rather strikingly different in the two malignant renal SFTs with dedifferentiation. While a patient developed multiple small lung nodules 4 months post-operatively [
8], the other patient was disease-free after 15 months of follow-up [
7]. Our patient has been well without evidence of recurrence or metastasis for 30 months. Some studies indicated that extrapleural SFTs had similar prognosis as the pleural counterpart, and a tumor with malignant histological feature was associated with recurrence and metastasis [
3,
14], but other studies showed that extrapleural SFTs tended to have a favorable outcome than pleural ones, even those with malignant histological features [
11,
15]. Studies also showed that deep-seated locations, over-expression of p53 and p16, loss of CD34 immunostaining and the presence of dedifferentiated areas may indicate more aggressive behaviors [
6]. Complete surgical excision and long-term follow-up are generally recommended for patients with extrapleural SFTs [
15]. Besides, due to the rich vascularity and possible origin from pericytes, antiangiogenic therapy, especially for the advanced cases is also under clinical investigation [
16].
1,4
This article has been 
